R W Johnson Pharmaceutical Research Institute
Raritan, New Jersey, 088690602, United States
NCT Number: NCT00002249
To determine the safety and pharmacokinetics of L-ofloxacin (RWJ 25213) in patients with HIV infection.
Looking for future studies?
Notify Me18 year and older
Male
Interventional
Phase 1
Raritan, New Jersey, 088690602, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients must have the following:
HIV infection.
Exclusion criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Patients with the following prior conditions are excluded:
Prior Medication:
Excluded:
Use of any investigational agent within 7 days of entry into study. Use of any medication within 3 days prior to entry (7 days for AZT). Alcohol or drug abuse.
R W Johnson Pharmaceutical Research Institute
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05510908
AIDS Related Lymphoma, AIDS-Related Kaposi Sarcoma
La Jolla, California, United States
View Trial DetailsNCT07750834
Acquired Immunodeficiency Syndrome, Behavior
Khartoum, Omdurman, Sudan
View Trial DetailsNCT06012136
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Las Vegas, Nevada, United States
View Trial DetailsNCT05911360
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Phoenix, Arizona, United States
View Trial Details